Marc Tessier-lavigne - Net Worth and Insider Trading
Marc Tessier-lavigne Net Worth
The estimated net worth of Marc Tessier-lavigne is at least $44 Million dollars as of 2025-04-30. Marc Tessier-lavigne is the Director of Denali Therapeutics Inc and owns about 2,107,225 shares of Denali Therapeutics Inc (DNLI) stock worth over $35 Million. Marc Tessier-lavigne is the Director of Juno Therapeutics Inc and owns about 75,000 shares of Juno Therapeutics Inc (JUNO) stock worth over $7 Million. Marc Tessier-lavigne is also the Director of Regeneron Pharmaceuticals Inc and owns about 2,269 shares of Regeneron Pharmaceuticals Inc (REGN) stock worth over $1 Million. Besides these, Marc Tessier-lavigne also holds Agios Pharmaceuticals Inc (AGIO) . Details can be seen in Marc Tessier-lavigne's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Marc Tessier-lavigne has not made any transactions after 2022-11-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Marc Tessier-lavigne
Marc Tessier-lavigne Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Marc Tessier-lavigne owns 5 companies in total, including Denali Therapeutics Inc (DNLI) , Regeneron Pharmaceuticals Inc (REGN) , and Agios Pharmaceuticals Inc (AGIO) among others .
Click here to see the complete history of Marc Tessier-lavigne’s form 4 insider trades.
Insider Ownership Summary of Marc Tessier-lavigne
Ticker | Company | Transaction Date | Type of Owner |
---|---|---|---|
DNLI | Denali Therapeutics Inc | 2022-11-23 | director |
REGN | Regeneron Pharmaceuticals Inc | 2022-10-03 | director |
AGIO | Agios Pharmaceuticals Inc | 2013-07-23 | director |
![]() | ![]() | 2016-06-17 | director |
![]() | ![]() | 2011-12-12 | director |
Marc Tessier-lavigne Latest Holdings Summary
Marc Tessier-lavigne currently owns a total of 4 stocks. Among these stocks, Marc Tessier-lavigne owns 2,107,225 shares of Denali Therapeutics Inc (DNLI) as of November 23, 2022, with a value of $35 Million and a weighting of 79.17%. Marc Tessier-lavigne owns 75,000 shares of Juno Therapeutics Inc (JUNO) as of December 18, 2014, with a value of $7 Million and a weighting of 14.72%. Marc Tessier-lavigne also owns 2,269 shares of Regeneron Pharmaceuticals Inc (REGN) as of October 3, 2022, with a value of $1 Million and a weighting of 3.07%. The other 1 stocks Agios Pharmaceuticals Inc (AGIO) have a combined weighting of 3.05% among all his current holdings.
Latest Holdings of Marc Tessier-lavigne
Ticker | Company | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
DNLI | Denali Therapeutics Inc | 2022-11-23 | 2,107,225 | 16.65 | 35,085,296 |
JUNO | Juno Therapeutics Inc | 2014-12-18 | 75,000 | 86.96 | 6,522,000 |
REGN | Regeneron Pharmaceuticals Inc | 2022-10-03 | 2,269 | 598.76 | 1,358,586 |
AGIO | Agios Pharmaceuticals Inc | 2013-07-23 | 45,454 | 29.69 | 1,349,529 |
Holding Weightings of Marc Tessier-lavigne
Marc Tessier-lavigne Form 4 Trading Tracker
According to the SEC Form 4 filings, Marc Tessier-lavigne has made a total of 11 transactions in Denali Therapeutics Inc (DNLI) over the past 5 years, including 0 buys and 11 sells. The most-recent trade in Denali Therapeutics Inc is the sale of 20,000 shares on November 23, 2022, which brought Marc Tessier-lavigne around $609,600.
According to the SEC Form 4 filings, Marc Tessier-lavigne has made a total of 0 transactions in Juno Therapeutics Inc (JUNO) over the past 5 years. The most-recent trade in Juno Therapeutics Inc is the sale of 0 shares on December 18, 2014, which brought Marc Tessier-lavigne around $0.
According to the SEC Form 4 filings, Marc Tessier-lavigne has made a total of 6 transactions in Regeneron Pharmaceuticals Inc (REGN) over the past 5 years, including 0 buys and 6 sells. The most-recent trade in Regeneron Pharmaceuticals Inc is the sale of 10,838 shares on October 3, 2022, which brought Marc Tessier-lavigne around $8 Million.
More details on Marc Tessier-lavigne's insider transactions can be found in the Insider Trading History of Marc Tessier-lavigne table.Insider Trading History of Marc Tessier-lavigne
- 1
Marc Tessier-lavigne Trading Performance
Marc Tessier-lavigne Ownership Network
Ownership Network List of Marc Tessier-lavigne
Ownership Network Relation of Marc Tessier-lavigne

Marc Tessier-lavigne Owned Company Details
What does Denali Therapeutics Inc do?
Who are the key executives at Denali Therapeutics Inc?
Marc Tessier-lavigne is the director of Denali Therapeutics Inc. Other key executives at Denali Therapeutics Inc include director & President and CEO Ryan J. Watts , COO and Secretary Alexander O. Schuth , and Chief Medical Officer Carole Ho .
Denali Therapeutics Inc (DNLI) Insider Trades Summary
Over the past 18 months, Marc Tessier-lavigne made no insider transaction in Denali Therapeutics Inc (DNLI). Other recent insider transactions involving Denali Therapeutics Inc (DNLI) include a net sale of 24,356 shares made by Vicki L Sato , a net sale of 194,212 shares made by Steve E. Krognes , and a net sale of 114,066 shares made by Ryan J. Watts .
In summary, during the past 3 months, insiders sold 0 shares of Denali Therapeutics Inc (DNLI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 526,480 shares of Denali Therapeutics Inc (DNLI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 526,480 shares.
Denali Therapeutics Inc (DNLI)'s detailed insider trading history can be found in Insider Trading Tracker table.
Denali Therapeutics Inc Insider Transactions
Marc Tessier-lavigne Mailing Address
Above is the net worth, insider trading, and ownership report for Marc Tessier-lavigne. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Marc Tessier-lavigne's mailing address is: South San Francisco Ca 94080.